www.youtube.com/watch?v=DZb-35oV_7E

See more here:
Forks Over Knives – Trailer – Video

Read more from the original source:
Apollo Hospitals launches first White Dental Spa in Chennai

Emergent Financial Group, Inc. (www.emergentfinancial.com) today announced the completion of a $11.8 million private placement transaction for Tenex Health Inc.(www.tenexhealth.com), a California-based medical technology company developing the FAST™ Procedure (Focused Aspiration of Scar Tissue) for the treatment of tendon injuries (www.fastprocedure.com). The private investment in a public equity (PIPE) financing was part of a reverse merger with U.S.-listed Direct Pet Health Holdings, Inc. (OTC:DPHG). Emergent Financial Group acted as the sole placement agent of common stock on behalf of Tenex Health.

“Through the efforts and guidance from Emergent Financial, we were able to quickly and effectively raise the funds to galvanize the growth of our company”

Emergent Financial Group is proud to be associated with Tenex Health and their revolutionary product that was developed in collaboration with the Mayo Clinic. Due to the overwhelming response from potential investors, Tenex Health increased the size of the offering from the original amount of $8.0 million to $11.8 million. Commenting on the successful equity offering, Emergent Financial CEO Peter Voldness stated: “The Tenex Health offering was a success by every measure. The offering was quickly oversubscribed by investors, including prominent orthopedic surgeons across the country that recognized the first mover advantage of the new therapy platform.” Additionally, Tenex was recently named by Forbes magazine as the top rated medical device company in their 2011 list of America's 100 Most Promising Companies.

“Through the efforts and guidance from Emergent Financial, we were able to quickly and effectively raise the funds to galvanize the growth of our company,” said Jagi Gill, CEO and Founder of Tenex Health Inc. Jagi Gill also added: “The financing has allowed us to fully integrate manufacturing and production capabilities with operations and sales as well as expand our physician and consumer marketing campaigns surrounding the FAST procedure. With such a comprehensive talent and resource pool, we can more effectively deliver our compelling therapy to the marketplace and build a robust product pipeline.”

Source Emergent Financial Group, Inc.

Read more here:
Emergent Financial Group raises $11.8M for Tenex Health

BLOOMINGTON, Minn.–(BUSINESS WIRE)–

Emergent Financial Group, Inc. (www.emergentfinancial.com) today announced the completion of a $11.8 million private placement transaction for Tenex Health Inc.(www.tenexhealth.com), a California-based medical technology company developing the FAST™ Procedure (Focused Aspiration of Scar Tissue) for the treatment of tendon injuries (www.fastprocedure.com). The private investment in a public equity (PIPE) financing was part of a reverse merger with U.S.-listed Direct Pet Health Holdings, Inc. (OTC:DPHG.PK – News). Emergent Financial Group acted as the sole placement agent of common stock on behalf of Tenex Health.

Emergent Financial Group is proud to be associated with Tenex Health and their revolutionary product that was developed in collaboration with the Mayo Clinic. Due to the overwhelming response from potential investors, Tenex Health increased the size of the offering from the original amount of $8.0 million to $11.8 million. Commenting on the successful equity offering, Emergent Financial CEO Peter Voldness stated: “The Tenex Health offering was a success by every measure. The offering was quickly oversubscribed by investors, including prominent orthopedic surgeons across the country that recognized the first mover advantage of the new therapy platform.” Additionally, Tenex was recently named by Forbes magazine as the top rated medical device company in their 2011 list of America's 100 Most Promising Companies.

“Through the efforts and guidance from Emergent Financial, we were able to quickly and effectively raise the funds to galvanize the growth of our company,” said Jagi Gill, CEO and Founder of Tenex Health Inc. Jagi Gill also added: “The financing has allowed us to fully integrate manufacturing and production capabilities with operations and sales as well as expand our physician and consumer marketing campaigns surrounding the FAST procedure. With such a comprehensive talent and resource pool, we can more effectively deliver our compelling therapy to the marketplace and build a robust product pipeline.”

About Tenex Health Inc.

Tenex Health, Inc. (www.tenexhealth.com) develops and markets innovative therapies for the treatment of tendon pain due to trauma or repetitive motion injuries. The minimally invasive procedure, known as FAST™ (Focused Aspiration of Scar Tissue), utilizes the company’s proprietary TX1 Tissue Removal System to debride and aspirate diseased soft tissue and bone spurs in an outpatient setting using local anesthetic (www.fastprocedure.com). Since the surrounding healthy tendon tissue is not disturbed, patients enjoy less discomfort and faster recovery times versus traditional open surgical procedures. The entire procedure is completed under local anesthesia and usually within 15 minutes.

About Emergent Financial Group, Inc. (www.emergentfinancial.com)

Emergent Financial Group provides investment banking services for early stage growth companies in healthcare. By specializing on innovative healthcare companies, Emergent has developed an understanding of these companies, their entrepreneurial managers, and their highly specialized financing needs.

Read more from the original source:
Emergent Financial Group Completes $11.8 Million PIPE Financing for Tenex Health Inc.

See the rest here:
Lifeline Scientific – Trading Update

Read this article:
Taglich Brothers Initiates Coverage on PLC Systems Inc.

NEWARK, Del.–(BUSINESS WIRE)–

SDIX (NASDAQ: SDIX – News), a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic and food safety applications, and BD Diagnostics, a segment of BD (Becton Dickinson and Company), a leading global medical technology company, today announced the signing of a comprehensive agreement whereby the two companies will collaborate in the development of a microbiology detection solution. The collaboration will combine SDIX’s expertise in development of high performance antibodies with BD’s expertise in diagnostic system development. The collaboration objective is to commercialize a novel system to address market needs for faster time to results and for accurate detection of microorganisms.

Under the agreement, SDIX will provide BD Diagnostics access to its proven antibody technology and a non-exclusive license to its patented bacteria phage technology. BD will pay SDIX a $1.25M upfront fee for a combination of license fees, technology access fees, and paid-for research during system development. In addition to the upfront payment, the agreement provides up to $2.5M in milestone payments and royalties on product sales incorporating SDIX’s patented technology. Upon commercialization of this system SDIX and BD will be engaged in a long term agreement for the supply of antibodies from SDIX to BD.

Francis DiNuzzo, SDIX’s President and CEO commented, “We are excited to be working with a world class organization like BD. This agreement demonstrates our strengths in the design and production of novel, highly specific antibodies and our knowledge and experience in developing antibody based detection systems.” Mr. DiNuzzo went on to say, “The combination of SDIX’s antibodies together with the assay and platform capabilities of BD will enable the partnership to deliver a highly valuable system that we expect to advance microbial detection in many very valuable applications. We are pleased with the opportunity to collaborate with such a capable and well known organization.”

About SDIX (www.sdix.com)

SDIX is a biotechnology company with a core expertise in creating better antigens, better antibodies and better assays for the pharmaceutical, biotechnology and food safety markets. For over 20 years, SDIX has been a leading immune-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives. In the life science market, SDIX’s technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs and provide antibodies and assays for the diagnosis of disease. In the food safety market, SDIX continues to expand its footprint as an international supplier of rapid pathogen test technologies that enable more accurate and cost-effective results.

This news release may contain forward-looking statements reflecting SDIX’s current expectations. When used in this press release, words like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “can”, “goal”, “potential”, “will”, “should”, “plan” and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX’s public filings with the U.S. Securities and Exchange Commission.

See original here:
SDIX Announces Collaboration Agreement with BD Diagnostics

Go here to read the rest:
Smith & Nephew Reaches Settlement With US Government

www.youtube.com/watch?v=YATNd-cq4A4

Read the rest here:
Greenway Medical Technologies celebrates IPO and rings the NYSE Opening Bell – Video

Read more from the original source:
Who is in the news? Kevin Goodwin

www.youtube.com/watch?v=qd70mrH5uiI

Follow this link:
Ophthalmic Medical Technology Profile – Video

Read the rest here:
SenoSENSE Medical Receives Health Canada Investigational Testing Approval for Densitrode(TM) Technology

SAN DIEGO, Feb. 2, 2012 /PRNewswire/ — CareFusion Corp. (NYSE: CFN – News), a leading, global medical technology company, today reported results for the three and six months ended Dec. 31, 2011.  

“Our second quarter results were led by strong performance across the Medical Systems segment, with our three major businesses achieving positive gains and positioning us well for the second half of the year,” said Kieran Gallahue, chairman and CEO. “These results were partially offset by our performance in the Procedural Solutions segment, as we indicated in our preliminary earnings report last month. We continue to believe that our highly differentiated Procedural Solutions products will grow faster than the market and remain meaningful contributors to our long-term performance.

“We continued to make good progress on our efforts to build our foundation and to invest in areas that will help simplify how we do business so we can expand margins and accelerate top-line growth over the long term. We remain committed to our long-term growth targets and are confident we will make progress against these goals this fiscal year.”

Second Quarter Results

The company reported revenue for the second quarter of fiscal 2012 of $915 million, compared to $886 million in the second quarter of fiscal 2011, an increase of 3 percent on a reported and constant currency basis.

Operating income was $143 million, an increase of 17 percent compared to $122 million in the prior year period. Excluding nonrecurring items, adjusted operating income for the second quarter was unchanged at $150 million.

Operating expenses totaled $314 million in the second quarter. Excluding nonrecurring items, adjusted operating expenses were $307 million, an increase of 4 percent over the prior year period, primarily driven by operating expenses from Rowa Technologies, which the company acquired in August 2011. In addition, the company increased investments in research and development during the quarter and benefited from ongoing cost-savings initiatives in the company's administrative support functions.

The company reported income from continuing operations in the second quarter of $95 million, or $0.42 per diluted share. Adjusted income from continuing operations increased 4 percent from the prior year period to $99 million, or $0.44 per diluted share. The adjusted tax rate was 25.2 percent for the second quarter.

Medical Systems

Second quarter revenue for the Medical Systems segment increased 9 percent from the prior year period on a reported and constant currency basis to $571 million, driven by strong sales across the segment. The company's Dispensing Technologies business, which grew in part from a contribution from the first-quarter acquisition of Rowa Technologies, also delivered its second strongest first-half organic revenue and committed contract performance in its history. The Infusion Systems business also achieved solid revenue growth, driven by installations of a record number of competitive channels during the quarter.

The revenue growth resulted in higher segment profit for the quarter, which increased 27 percent from the prior year period to $121 million. Adjusted segment profit increased 12 percent from the prior year period to $124 million.

Procedural Solutions

Second quarter revenue for the Procedural Solutions segment decreased 5 percent from the prior year period on a reported and constant currency basis. The decrease was driven, in part, by the loss of sales from divesting the company's OnSite Services business in March 2011. Net of the OnSite Services business divestiture, segment revenues decreased 2 percent from the prior year period. The segment results were also affected by decreased sales of respiratory disposables products in the Specialty Disposables business.

The revenue decline led to a decrease in segment profit of 19 percent from the prior year period to $22 million, and adjusted segment profit decreased 33 percent to $26 million.  

Six-Month Results

For the first six months of fiscal 2012, revenue increased 4 percent from the prior year period to $1.76 billion. Operating income increased to $251 million from $201 million in the prior year period. Income from continuing operations was $162 million, or $0.72 per diluted share. Adjusted income from continuing operations increased 10 percent from the prior year period to $175 million, or $0.78 per diluted share.

Operating expenses in the first six months totaled $633 million, or $615 million on an adjusted basis.  

Segment results for the six months ended Dec. 31, 2011 and 2010 are as follows:

Medical Systems

1H FY12

1H FY11

Y/Y

Revenue

$1,080 million

$991 million

9%

Segment Profit

$209 million

$163 million

28%

Adjusted Segment Profit

$219 million

$201 million

9%

Procedural Solutions

1H FY12

1H FY11

Y/Y

Revenue

$679 million

$706 million

(4)%

Segment Profit

$42 million

$38 million

11%

Adjusted Segment Profit

$50 million

$67 million

(25)%

Additional second quarter and recent highlights included:

Launching the Pyxis® Enterprise System (ES) platform, the next generation of CareFusion's industry-leading automated dispensing systems that will enable hospital customers to simplify and standardize the medication management process, both within a single facility and across an entire health system. Notable product releases on the platform are the Pyxis Enterprise Server, Pyxis MedStation® ES and CareFusion Coordination Engine. Launching the CareFusion Ventilation System, combining CareFusion's industry-leading ventilators with new interoperability and analytics software to better address clinical and operational challenges in patient care. Receiving federal data encryption certification for the Alaris® System, becoming the first and only infusion system to receive the National Institute of Standards and Technology certification now required for infusion devices operating on the U.S. Department of Veterans Affairs' hospital networks. Earning top rankings from KLAS, an independent market research firm that awarded MedMined® Services the No. 1 ranking in its 2011 annual report on infection control and monitoring providers, and from MD Buyline, which recognized Pyxis® technologies as number one in user satisfaction ratings in its December 2011 quarterly report. Launching the Nicolet™ EEG (Electroencephalography) Wireless Amplifier, a device that effectively captures high-resolution brain wave data to be used with the Nicolet Neurodiagnostic system.

Fiscal 2012 Outlook

CareFusion continues to expect full-year consolidated revenue to grow 3 to 5 percent on a constant currency basis compared to fiscal 2011 revenue of $3.53 billion. The company narrowed its previous full-year guidance range for adjusted diluted EPS from continuing operations of $1.75 to $1.90 to a new range of $1.75 to $1.85.

The guidance is based on an assumed diluted weighted average outstanding share count of approximately 227 million.

Conference Call

CareFusion will host a conference call today at 2 p.m. PST (5 p.m. EST) to discuss earnings results for the second quarter fiscal 2012.

To access the call and corresponding slide presentation, visit the Investors page at www.carefusion.com. Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

Investors and other interested parties may also access the call by dialing (800) 901-5247 within the U.S. or (617) 786-4501 from outside the U.S., and use the access code 28588340. A replay of the conference call will be available from 5 p.m. PST (8 p.m. EST) on Feb. 2 through 8:59 p.m. PST (11:59 p.m. EST) on Feb. 9 and can be accessed by dialing (888) 286-8010 in the U.S. or (617) 801-6888 internationally and using the access code 19918894.

About CareFusion Corporation

CareFusion (NYSE: CFN – News) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife™ and LTV® series ventilation and respiratory products, ChloraPrep® products, MedMined® services for data mining surveillance, Nicolet™ neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.

###

Use of Non-GAAP Financial Measures by CareFusion Corporation

This CareFusion news release presents non-GAAP financial measures that exclude certain amounts, as follows: “adjusted operating expenses” and “adjusted operating income”, which exclude nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges; “adjusted income from continuing operations”, “adjusted diluted earnings per share from continuing operations” and “adjusted tax rate”, which exclude nonrecurring items primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges and nonrecurring tax items; and “adjusted segment profit”, which excludes nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.

The most directly comparable measure for these non-GAAP financial measures are operating expenses, operating income, income from continuing operations, diluted earnings per share from continuing operations, tax rate, and segment profit (the most comparable GAAP measures). The company has included below unaudited adjusted financial information for the quarters and six months ended Dec. 31, 2011 and 2010, which includes a reconciliation of GAAP to non-GAAP financial measures.

In addition, CareFusion presents the non-GAAP financial measure “adjusted income from continuing operations per diluted share” on a forward-looking basis. CareFusion is unable to provide a quantitative reconciliation of this forward-looking non-GAAP financial measure to the most directly comparable forward-looking GAAP measure, because the company cannot reliably forecast restructuring and acquisition integration costs, and other nonrecurring costs. Please note that the unavailable reconciling items could significantly impact CareFusion's future financial results. A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding CareFusion's financial condition and results of operations is included as Exhibit 99.3 to CareFusion's report on Form 8-K filed with the Securities and Exchange Commission on Feb. 2, 2012.

Cautions Concerning Forward-looking Statements

The CareFusion news release and the information contained herein contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in CareFusion's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; current economic conditions have and may continue to adversely affect our results of operations and financial condition; we may be unable to realize any benefit from our cost reduction and restructuring efforts and our profitability may be hurt or our business otherwise might be adversely affected; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; we are currently operating under an amended consent decree with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. The CareFusion news release and the information contained herein reflect management's views as of Feb. 2, 2012. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CAREFUSION CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Quarter Ended

Six Months Ended

December 31,

December 31,

(in millions, except per share amounts)

2011

2010

2011

2010

Revenue

$

915

$

886

$

1,759

$

1,697

Cost of Products Sold

458

441

875

839

Gross Margin

457

445

884

858

Selling, General and Administrative Expenses

267

270

540

542

Research and Development Expenses

40

36

79

76

Restructuring and Acquisition Integration Charges

7

17

14

39

Operating Income

143

122

251

201

Interest Expense and Other, Net

17

20

42

43

Income Before Income Tax

126

102

209

158

Provision for Income Tax

31

29

47

49

Income from Continuing Operations

95

73

162

109

Income from Discontinued Operations, Net of Tax

–

3

–

5

Net Income

$

95

$

76

$

162

$

114

Per Share Amounts: (1)

Basic Earnings per Common Share:

Continuing Operations

$

0.42

$

0.32

$

0.72

$

0.49

Discontinued Operations

$

–

$

0.01

$

–

$

0.02

Basic Earnings per Common Share

$

0.42

$

0.34

$

0.72

$

0.51

Diluted Earnings per Common Share:

Continuing Operations

$

0.42

$

0.32

$

0.72

$

0.49

Discontinued Operations

$

–

$

0.01

$

–

$

0.02

Diluted Earnings per Common Share

$

0.42

$

0.34

$

0.72

$

0.51

Weighted-Average Number of Common Shares Outstanding:

Basic

224.7

222.8

224.3

222.4

Diluted

226.6

224.5

226.5

224.2

(1)

Earnings per share calculations are performed separately for each component presented.  Therefore, the sum of the per share components from the table may not equal the per share amounts presented.

CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)

Quarter Ended December 31, 2011

Nonrecurring

(in millions, except per share amounts)

GAAP

Items (1)

Adjusted (2)

Revenue (3)

$

915

$

–

$

915

Cost of Products Sold

458

–

458

Gross Margin

457

–

457

Selling, General and Administrative Expenses

267

–

267

Research and Development Expenses

40

–

40

Restructuring and Acquisition Integration Charges

7

(7)

–

Operating Income

143

7

150

Interest Expense and Other, Net

17

–

17

Income Before Income Tax

126

7

133

Provision for Income Tax

31

3

34

Net Income

$

95

$

4

$

99

Per Share Amounts: (4)

Basic Earnings per Common Share

$

0.42

$

0.02

$

0.44

Diluted Earnings per Common Share

$

0.42

$

0.02

$

0.44

Weighted-Average Number of Common Shares Outstanding:

Basic

224.7

224.7

224.7

Diluted

226.6

226.6

226.6

Effective Tax Rate (5)

24.7%

27.0%

25.2%

____________

(1)

Reflects nonrecurring charges primarily related to restructuring.  

(2)

Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.

(3)

Revenues increased $29 million or 3% for the quarter ended December 31, 2011 compared to 2010, on a constant currency basis, the increase is also 3%.

(4)

Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

(5)

Effective tax rate calculations are performed based on whole dollar amounts, and therefore may not equal the calculations based on amounts rounded in millions presented in the table above.

CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)

Six Months Ended December 31, 2011

Nonrecurring

(in millions, except per share amounts)

GAAP

Items (1)

Adjusted (2)

Revenue (3)

$

1,759

$

–

$

1,759

Cost of Products Sold

875

–

875

Gross Margin

884

–

884

Selling, General and Administrative Expenses

540

(4)

536

Research and Development Expenses

79

–

79

Restructuring and Acquisition Integration Charges

14

(14)

–

Operating Income

251

18

269

Interest Expense and Other, Net

42

–

42

Income Before Income Tax

209

18

227

Provision for Income Tax

47

5

52

Net Income

$

162

$

13

$

175

Per Share Amounts: (4)

Basic Earnings per Common Share

$

0.72

$

0.06

$

0.78

Diluted Earnings per Common Share

$

0.72

$

0.06

$

0.78

Weighted-Average Number of Common Shares Outstanding:

Basic

224.3

224.3

224.3

Diluted

226.5

226.5

226.5

Effective Tax Rate (5)

22.5%

26.1%

22.7%

____________

(1)

Reflects nonrecurring charges primarily related to nonrecurring restructuring charges and the spinoff.  

(2)

Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.

(3)

Revenues increased $62 million or 4% for the six months ended December 31, 2011 compared to 2010, on a constant currency basis, the increase is 3%.

(4)

Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

(5)

Effective tax rate calculations are performed based on whole dollar amounts, and therefore may not equal the calculations based on amounts rounded in millions presented in the table above.

CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)

Quarter Ended December 31, 2010

Discontinued

Nonrecurring

(in millions, except per share amounts)

GAAP

Operations (1)

Items (2)

Adjusted (3)

Revenue

$

886

$

–

$

–

$

886

Cost of Products Sold

441

–

–

441

Gross Margin

445

–

–

445

Selling, General and Administrative Expenses

270

–

(11)

259

Research and Development Expenses

36

–

–

36

Restructuring and Acquisition Integration Charges

17

–

(17)

–

Operating Income

122

–

28

150

Interest Expense and Other, Net

20

–

–

20

Income Before Income Tax

102

–

28

130

Provision for Income Tax

29

–

6

35

Income from Continuing Operations

73

–

22

95

Income from Discontinued Operations, Net of Tax

3

(3)

–

–

–

Net Income

$

76

$

(3)

$

22

$

95

Per Share Amounts: (4)

Basic Earnings per Common Share

$

0.34

$

(0.01)

$

0.10

$

0.42

Diluted Earnings per Common Share

$

0.34

$

(0.01)

$

0.10

$

0.42

Weighted-Average Number of Common Shares Outstanding:

Basic

222.8

222.8

222.8

222.8

Diluted

224.5

224.5

224.5

224.5

Effective Tax Rate (5)

28.8%

n/a

20.3%

26.9%

____________

(1)

Reflects the impact of the divestiture of the International Surgical Products (ISP) business.  The ISP business was divested in April 2011, and has been classified as discontinued operations.

(2)

Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring tax items.  

(3)

Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.

(4)

Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

(5)

Effective tax rate calculations are performed based on whole dollar amounts, and therefore may not equal the calculations based on amounts rounded in millions presented in the table above.

CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)

Six Months Ended December 31, 2010

Discontinued

Nonrecurring

(in millions, except per share amounts)

GAAP

Operations (1)

Items (2)

Adjusted (3)

Revenue

$

1,697

$

–

$

–

$

1,697

Cost of Products Sold

839

–

–

839

Gross Margin

858

–

–

858

Selling, General and Administrative Expenses

542

–

(28)

514

Research and Development Expenses

76

–

–

76

Restructuring and Acquisition Integration Charges

39

–

(39)

–

Operating Income

201

–

67

268

Interest Expense and Other, Net

43

–

–

43

Income Before Income Tax

158

–

67

225

Provision for Income Tax

49

–

17

66

Income from Continuing Operations

109

–

50

159

Income from Discontinued Operations, Net of Tax

5

(5)

–

–

Net Income

$

114

$

(5)

$

50

$

159

Per Share Amounts: (4)

Basic Earnings per Common Share

$

0.51

$

(0.02)

$

0.23

$

0.72

Diluted Earnings per Common Share

$

0.51

$

(0.02)

$

0.22

$

0.71

Weighted-Average Number of Common Shares Outstanding:

Basic

222.4

222.4

222.4

222.4

Diluted

224.2

224.2

224.2

224.2

Effective Tax Rate (5)

30.8%

n/a

24.7%

29.0%

____________

(1)

Reflects the impact of the divestiture of the International Surgical Products (ISP) business.  The ISP business was divested in April 2011, and has been classified as discontinued operations.

(2)

Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring tax items.  

(3)

Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.

(4)

Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

(5)

Effective tax rate calculations are performed based on whole dollar amounts, and therefore may not equal the calculations based on amounts rounded in millions presented in the table above.

CAREFUSION CORPORATION

ADJUSTED SEGMENT FINANCIAL INFORMATION

(UNAUDITED)

Quarter Ended December 31, 2011

Nonrecurring

(in millions)

GAAP

Items (1)

Adjusted (2)

Medical Systems

Revenue

$

571

$

–

$

571

Segment Profit

$

121

$

3

$

124

Procedural Solutions

Revenue

$

344

$

–

$

344

Segment Profit

$

22

$

4

$

26

Six Months Ended December 31, 2011

Nonrecurring

(in millions)

GAAP

Items (3)

Adjusted (2)

Medical Systems

Revenue

$

1,080

$

–

$

1,080

Segment Profit

$

209

$

10

$

219

Procedural Solutions

Revenue

$

679

$

–

$

679

Segment Profit

$

42

$

8

$

50

Quarter Ended December 31, 2010

Nonrecurring

(in millions)

GAAP

Items (4)

Adjusted (2)

Medical Systems

Revenue

$

523

$

–

$

523

Segment Profit

$

95

$

16

$

111

Procedural Solutions

Revenue

$

363

$

–

$

363

Segment Profit

$

27

$

12

$

39

Six Months Ended December 31, 2010

Nonrecurring

(in millions)

GAAP

Items (4)

Adjusted (2)

Medical Systems

Revenue

$

991

$

–

$

991

Segment Profit

$

163

$

38

$

201

Procedural Solutions

Revenue

$

706

$

–

$

706

Segment Profit

$

38

$

29

$

67

____________

(1)

Reflects nonrecurring charges primarily related to restructuring.  

(2)

Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.

(3)

Reflects nonrecurring charges primarily related to nonrecurring restructuring charges and the spinoff.

(4)

Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.  Certain nonrecurring costs previously reported were applicable to the International Surgical Products (ISP) business and therefore were reclassified to be reflected as part of that business.

CAREFUSION CORPORATION

SEGMENT AND SELECT BUSINESS LINE REVENUES

(UNAUDITED)

Quarter Ended

Six Months Ended

December 31,

December 31,

(in millions)

2011

2010 (1)

Percent

Change

2011

2010 (1)

Percent

Change

Medical Systems

Dispensing Technologies

$

257

$

229

12%

$

494

$

434

14%

Infusion Systems

239

223

7

445

415

7

Respiratory Technologies

69

65

6

129

130

(1)

Other

6

6

–

12

12

–

Total Medical Systems

$

571

$

523

9

$

1,080

$

991

9

Procedural Solutions

Infection Prevention

$

142

$

142

-%

$

280

$

277

1%

Medical Specialties

79

78

1

157

156

1

Specialty Disposables

65

73

(11)

131

143

(8)

Other

58

70

(17)

111

130

(15)

Total Procedural Solutions

$

344

$

363

(5)

$

679

$

706

(4)

Total CareFusion

$

915

$

886

3%

$

1,759

$

1,697

4%

____________

(1)

Previously reported GAAP amounts have been adjusted to reflect the impact of the divestiture of the International Surgical Products (ISP) business. The ISP business was divested in April 2011, and has been classified as discontinued operations.

(Logo:  http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)

More here:
CareFusion Reports Second Quarter Fiscal 2012 Results

www.youtube.com/watch?v=2qa6s2VGHIU

Read more here:
Medical Technologists Program – Video

Wednesday, February 01 10:41:46

Over the last twelve months, medical technology companies publicly announced the investment of around E170m and the creation of an estimated 875 jobs, according to the Irish Medical Device Association (IMDA).

The figures come as the IMDA published its four year strategy (2012 -2015) for the med-tech sector today.

The 250 medical technology companies in Ireland, which consists of both domestic and FDI companies, export E7.2 billion worth of product annually and employ 25,000 people – the highest number of people working in the industry in any country in Europe, per head of population.

Recent reports published by IBEC show that during 2012 approximately half of all medical technology companies in Ireland expect to recruit additional employees and two thirds of medical technology companies expect turnover to increase during in the next five years.

The ongoing investment and job creation reflects the vibrancy of the medical technology sector in Ireland according to Paraic Curtis, Incoming Chairman of the IMDA.

“The investment of approximately E170m is across a wide range of development, manufacturing and R and D projects. In total these investments will create almost 875 jobs in the coming years. 2012 has also started brightly,” he said.

“The industry is poised for rapid convergence between technologies which will result in more collaboration and new products in the drug device and smart device development,” said Mr Curtis.

“In weathering the global economic downturn, the med-tech sector has become more productive, innovative and competitive, and will undoubtedly be a key driver of Ireland's export-led growth in coming years. Having said that, the next four years will not be without challenges with global healthcare expenditure coming under mounting pressure the challenge will be to demonstrate technologies which add value and efficiency. Given the industry's existing capacity to adapt, it is in a strong position to address these challenges,” he added.

More:
Med tech firms create 875 jobs in 2011

Read more:
CONMED Corporation to Present at the 2012 Canaccord Genuity Musculoskeletal Conference

PRINCETON, N.J. & PARIS–(BUSINESS WIRE)– STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), announced today that the “APPOSITION III” clinical study successfully enrolled 1,000 patients suffering from a severe heart attack and that the final results of the examination 30 days after treatment will be presented during the upcoming EuroPCR international cardiology congress.

“Closing the study ahead of our projected timetable is a clear sign of the increasing adoption of our technology among cardiologists. The impressive interim clinical results reported two months ago should be confirmed by the final results and will prove that the Self-Apposing™ technology is the best solution for treating heart attack patients,” said Gonzague Issenmann, CEO and co-founder of STENTYS.

The STENTYS Self-Apposing™ Stent represents a major breakthrough: it solves the stent sizing dilemma that cardiologists are confronted with when treating heart attack patients with conventional stents. It “fits snugly” into the contour of a blood vessel, and its shape and diameter adapt to the anatomic changes of the coronary arteries during the post-AMI phase, avoiding a major complication of all other conventional stents: malapposition.

About STENTYS

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its Self-Apposing™ stent adapts to the anatomic changes of the artery in the post-infarction phase and thus prevents the malapposition problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.

Link:
STENTYS concludes clinical trial ahead of plan

Read the original post:
Nanostart-holding MagForce AG Announces Capital Increase from Authorized Capital

Read more:
Strongest Growth in US Peripheral Vascular Market to Come in Lower Extremity Indications

PLEASANTON, Calif., Feb. 1, 2012 (GLOBE NEWSWIRE) — ZELTIQ(R) Aesthetics, Inc. (Nasdaq:ZLTQ – News), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that Gordie Nye, Chief Executive Officer, is scheduled to present at the Leerink Swann 2012 Global Healthcare Conference in New York City.

Event: Leerink Swann 2012 Global Healthcare Conference
Date: Thursday, February 16, 2012
Time: 8 a.m. ET

An audio webcast of the Company's presentation will be available by visiting the investor relations section of ZELTIQ's website at www.coolsculpting.com. A replay of the presentation will be available for 30 days.

About ZELTIQ Aesthetics

ZELTIQ Aesthetics is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company's first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.

Excerpt from:
ZELTIQ Aesthetics, Inc. to Present at the Leerink Swann 2012 Global Healthcare Conference